Natera is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera’s team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage. Natera’s goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.
Science & Informatics
Science & Informatics
Natera’s genetic testing solutions combine proprietary molecular biology and bioinformatics. Our novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Our statistical algorithms combine these measurements with data available from the broader scientific community to determine the likelihood of a wide range of serious conditions with best-in-class accuracy and coverage. Our technology has been proven clinically and commercially in the prenatal testing space and we are actively researching its applications in the liquid biopsy space for developing products with oncology applications.
Now, our technology capabilities are being expanded beyond our own laboratory to lab customers worldwide via Constellation™, Natera’s cloud-based genetic data analysis software.
Natera is driven by a passion for elevating the science and utility of prenatal testing with highly accurate solutions for: non-invasive prenatal testing (NIPT), genetic carrier screening, preimplantation genetic testing (PGD/PGS), miscarriage testing and prenatal paternity testing. Using advances from the human genome project and powered by sophisticated proprietary bioinformatics algorithms, Natera’s comprehensive portfolio of prenatal tests, proven science and experienced genetic counseling services deliver highly accurate results that physicians and patients can trust.
Oncology Genetic Testing
The next generation of products being developed by Natera involves applying our proprietary molecular and bioinformatics approaches to the field of oncology diagnostics. Our ability to reliably analyze DNA at many thousands of loci at the scale of a single-molecule is very well suited for the early detection, therapy monitoring and recurrence monitoring of a wide variety of cancers.
Natera is currently working with some of the world’s leading cancer centers to collect samples and develop ‘‘liquid biopsy’’ tests to analyze circulating tumor DNA of common forms of the disease, including breast, ovarian, and lung cancer. Our goals are to reduce the need for invasive tumor biopsies, enable earlier detection of cancer and enhance treatment.